Kelly-Spratt, K.S. and Philipp-Staheli, J. and Gurley, K.E. and Hoon-Kim, K. and Knoblaugh, S. and Kemp, C.J. (2009) Inhibition of PI-3K restores nuclear p27(Kip1) expression in a mouse model of Kras-driven lung cancer. Oncogene, 28 (41). pp. 3652-3662. ISSN 1476-5594
Preview |
Text (Complete manuscript)
KempCOncogeneManuscript091509.pdf Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview |
Abstract
Reduced expression of the CDK inhibitor p27(Kip1) (p27) in human lung cancer correlates with tumor aggressiveness and poor prognosis. However, the regulation of p27 expression and the role of p27 during lung cancer are poorly understood. Urethane-induced lung tumors in mice frequently harbor mutations in the Kras oncogene, and in this study, we use this model to address the regulation of p27 during tumorigenesis. The Ras effector Akt is known to regulate p27 mRNA abundance by phosphorylating and inactivating the FOXO transcription factors. Phosphorylated Akt and FOXO proteins were both increased in lung tumors, correlating with a reduction in p27 mRNA transcript. Akt also directly phosphorylates p27 and regulates its nuclear/cytoplasmic localization. Tumors showed a reduced nuclear/cytoplasmic ratio of p27 protein, together with an increase in phosphorylated Thr197 p27 in the cytoplasmic pool. Treatment of lung tumor-bearing mice with the phosphoinositol-3 kinase inhibitor LY294002 induced a rapid decrease in phosphorylated Akt and phosphorylated p27, concomitant with an increase in nuclear p27. Germline p27 deficiency accelerated both the growth and malignant progression of urethane-induced lung tumors, and did so in a cell autonomous manner, confirming a causal role of p27 in tumor suppression. These results show that p27 is a potent barrier to the growth and malignant progression of Kras-initiated lung tumors. Further, the reduction of nuclear p27 in tumors is mediated by oncogene signaling pathways, which can be reversed by pharmacological agents.Oncogene advance online publication, 3 August 2009; doi:10.1038/onc.2009.226.
| Item Type: | Article or Abstract |
|---|---|
| Additional Information: | This article is available to subscribers only via the URL above. |
| DOI: | 10.1038/onc.2009.226 |
| PubMed ID: | 19648963 |
| NIHMSID: | NIHMS146026 |
| PMCID: | PMC2842079 |
| Grant Numbers: | R01 CA099517 |
| Keywords or MeSH Headings: | 1-Phosphatidylinositol 3-Kinase/*antagonists & inhibitors; Animals; Carcinoma, Non-Small-Cell Lung/chemically induced/enzymology/genetics/pathology; Cell Nucleus/*drug effects/genetics/metabolism; Chromones/pharmacology; Cyclin-Dependent Kinase Inhibitor p27/deficiency/*genetics/*metabolism; Disease Models, Animal; Enzyme Inhibitors/pharmacology; Gene Expression Regulation, Neoplastic/*drug effects; Humans; Lung Neoplasms/chemically induced/enzymology/*genetics/pathology; Mice; Morpholines/pharmacologyl; Mutation; Proto-Oncogene Proteins p21(ras)/genetics/*metabolism; RNA, Messenger/genetics/metabolism; Urethane/pharmacology |
| Subjects: | Diseases > Solid tumors > Lung cancer Cellular and Organismal Processes > Genetic processes > Transcription |
| Depositing User: | Library Staff |
| Date Deposited: | 15 Sep 2009 22:22 |
| Last Modified: | 14 Feb 2012 14:42 |
| URI: | http://authors.fhcrc.org/id/eprint/332 |
Repository Administrators Only
 |
View Item |
